Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system.
Our lead product candidate, rapastinel (GLYX-13), is in late-stage clinical development as an adjunctive therapy for patients with major depressive disorder who are unable to achieve an adequate response to their current anti-depressants. Rapastinel has shown rapid, substantial, and sustained antidepressant activity in Phase 2 clinical studies and has been well-tolerated, with none of the psychosis-like side effects that limit other drugs targeting NMDA receptors. Our second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development as a monotherapy for the treatment of major depressive disorder.
In July 2015, Naurex Inc. entered into a definitive agreement to be acquired by Allergan plc. The transaction was successfully closed in August 2015. For more information, please visit www.naurex.com or www.allergan.com.
Location: United States
Employees: 11-50
Total raised: $80M
Founded date: 2006
Investors 2
| Date | Name | Website |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Genesys Ca... | genesyscap... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 03.12.2014 | Series C | $80M | - | medcitynew... |
Mentions in press and media 14
| Date | Title | Description | Source |
| 27.07.2015 | Following Its $560M Acquisition, NU Drug Startup Naurex Laun... | This weekend Naurex, an Evanston-based biopharma company that creates depression-treating drugs, was... | bizjournal... |
| 28.01.2015 | 2014: A bumper year for the Midwest life sciences startups | Health IT: $562 million This data aggregation came from the BioEnterprise Midwest Healthcare Growth... | medcitynew... |
| 03.12.2014 | Naurex Raises $80M in Series C | EVANSTON, Ill, Biopharmaceutical company leveraging its unique platform to develop novel drugs for... | vcnewsdail... |
| 03.12.2014 | NU Biopharma Startup Naurex Raises $80M to Develop Drugs to ... | Naurex, a biopharmaceutical company born out of Northwestern that creates drugs to fight against dis... | bizjournal... |
| 03.12.2014 | Northwestern spinout Naurex raises $80M Series C to bring an... | The Chicago-area company says that in clinical proof-of-concept studies, GLYX-13 “was well-tolerated... | medcitynew... |
| 06.05.2014 | Naurex picks up $25M to get its depression drugs through PhI... | Evanston, IL's Naurex nailed down another $25 million in venture funding to accelerate its two-prong... | fiercebiot... |
| 17.12.2012 | VCs, corporate pharma investors put $38M behind Naurex’s new... | Naurex is developing what it says is a new mechanism of action for modulating the NMDA receptor, whi... | medcitynew... |
| 17.12.2012 | Naurex Raises $38M in Series B Financing | Naurex Inc., an Evanston, Illinois-based clinical-stage company focused on psychiatry and neurology,... | finsmes.co... |
| 17.12.2012 | Baxter joins Big Pharma funds on $38M B round for Naurex ant... | Baxter's new venture fund has stepped up to take the lead on a $38 million B round for Naurex, an Ev... | fiercebiot... |
| 17.12.2012 | Naurex Completes $38M Series B | EVANSTON, IL, Clinical-stage company developing innovative treatments to address unmet needs in ps... | vcnewsdail... |
Show more